Kurma Partners Makes €140M First Close on €250M VC Biotech Fund

Paris-based Kurma Partners announced a €140M first close on its fourth VC biotech fund, targeting a total fundraise of €250M by its final close in 2025.

In an October 3 news release, Kurma said its Biofund IV is seeking to make 16-20 new investments following a similar strategy to its three predecessor funds, which are “dedicated to companies developing innovative therapeutics, aiming for a balanced, risk-managed strategy, with investments for company creation as well as in established venture-stage companies.”

Kurma said the new fund has already made three investments, one in autoimmune company SciRhom, another in cancer immunotherapy company Avidicure, and the third in Memo Therapeutics.

View the press release here.